Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $122.00. The company's market cap stands at 150.58B, with a P/E ratio of 18.40 and a dividend yield of 2.6%.
On 2025-12-17, Gilead Sciences(GILD) stock traded between a low of $118.50 and a high of $122.07. Shares are currently priced at $122.00, which is +3.0% above the low and -0.1% below the high.
The Gilead Sciences(GILD)'s current trading volume is 7.54M, compared to an average daily volume of 7.15M.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
GILD News
If you are wondering whether Gilead Sciences is still a smart consideration after its big run, or if you are late to the party, this breakdown will help you ass...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield In...
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Gilead Sciences, with a price target of $140.00. Claim 50% Off TipRanks Prem...
Analyst ratings
72%
of 29 ratingsMore GILD News
(RTTNews) - Gilead Sciences (GILD) on Monday reported positive topline results from the Phase 3 ARTISTRY-2 trial. This trial looked at switching from BIKTARVY...
Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are v...
Looking at the universe of stocks we cover at Dividend Channel, on 12/15/25, Gilead Sciences Inc (Symbol: GILD), Merck & Co Inc (Symbol: MRK), and Horace Mann E...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel , our YieldBoo...